Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

Delayed Quote. Delayed  - 05/02 10:01:42 pm
115.93 USD   +0.14%
04/29 ZIMMER BIOMET : Shares its Financial Results for the First Quarter o..
04/28DJZimmer Biomet Raises Outlook as 1Q Results Top Views
04/28 ZIMMER BIOMET : Apr 28, 2016 Zimmer Biomet Holdings, Inc. Reports Fi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CEST

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ZIMMER BIOMET HOLDINGS INC
04/29 ZIMMER BIOMET : Shares its Financial Results for the First Quarter of 2016
04/28DJZimmer Biomet Raises Outlook as 1Q Results Top Views
04/28 ZIMMER BIOMET : Apr 28, 2016 Zimmer Biomet Holdings, Inc. Reports First Quarter ..
04/28 ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition, Fi..
04/28 ZIMMER BIOMET : beats Street 1Q forecasts
04/28 ZIMMER BIOMET : Reports First Quarter 2016 Financial Results
04/26 ZIMMER BIOMET : Apr 26, 2016 Zimmer Biomet Holdings to Present at Deutsche Bank ..
04/25 ZIMMER BIOMET : to Acquire Cayenne Medical
04/25 ZIMMER BIOMET : Apr 25, 2016 Zimmer Biomet Enters into Definitive Agreement to A..
04/25ZIMMER BIOMET HOLDINGS INC : quaterly earnings release
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials